Research programme: fibrotic disease therapeutics - Bristol-Myers Squibb/The Medical University of South Carolina
Latest Information Update: 17 Jul 2015
At a glance
- Originator Bristol-Myers Squibb; Medical University of South Carolina
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 15 Jul 2015 Early research in Fibrosis in USA (unspecified route)